Should I Buy PRA? PRA 2026 Analysis

Should You Buy ProAssurance Corp (PRA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

24.220

1 Day change

-0.08%

52 Week Range

24.410

Analysis Updated At

2026/01/30

Not a good buy right now. While the chart setup is mildly bullish (stacked moving averages and improving MACD), the stock is pressing near resistance with RSI near overbought, options positioning is heavily put-skewed (bearish/defensive), and the latest quarter showed a steep profitability collapse. For an impatient buyer who wants to act immediately, the risk/reward is not attractive at ~$24.23 without a clearer catalyst or pullback.

Technical Analysis

Trend/structure: Bullish moving-average stack (SMA_5 > SMA_20 > SMA_200) suggests an established uptrend. Momentum: MACD histogram is above zero and expanding (0.00506), supporting ongoing upside momentum. RSI(6)=69.33 is near overbought, implying upside may be limited near-term and a pause/pullback risk is rising. Levels: Pivot 24.186. Immediate resistance is tight overhead (R1 24.262, R2 24.309), meaning price is close to a supply zone; supports sit at S1 24.109 and S2 24.062. Quant pattern read: Similar-pattern projection implies modest upside next day/week (+0.57% / +1.26%) but slight weakness over a month (-0.95%), aligning with a near-term grind higher but limited follow-through. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): no signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning: Put open interest (1563) far exceeds call open interest (356), producing a very high OI put/call ratio (4.39) = strongly defensive/bearish positioning or heavy hedging. Activity: Reported option volume is essentially zero today (no put or call volume), so sentiment is inferred from positioning rather than fresh flow. Volatility: 30D IV ~25.13 with IV percentile ~33.6 and IV rank ~13.28 (not elevated). This suggests options are not pricing a major near-term move; the skew is more about protection than panic.

Technical Summary

Sell

Buy

Positive Catalysts

Technical uptrend remains intact (bullish MA alignment + improving MACD).
No negative news flow in the last week.
Upcoming earnings (2026-02-23 after hours) could reset expectations if profitability rebounds (consensus EPS est. ~0.22 provided in calendar).

Neutral/Negative Catalysts

with RSI near overbought, increasing the odds of a stall or pullback rather than an immediate clean breakout.

Financial Performance

Latest quarter: 2025/Q3. Revenue: $275.28M, down 1.12% YoY (slight contraction). Net income: $1.45M, down 91.20% YoY (sharp decline). EPS: $0.03, down 90.62% YoY (major earnings compression). Overall: The core concern is not revenue but the collapse in profitability, which undermines confidence in buying aggressively at current levels without evidence of margin/earnings recovery.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price-target change data was provided, so a recent Wall Street upgrade/downgrade trend cannot be confirmed from the dataset. Pros (typical bull case given available data): improving technical trend; potential earnings rebound into the next report. Cons (bear case supported by data): severe YoY earnings drop; defensive options positioning; lack of visible near-term catalysts/news.

Analyst Rating

Wall Street analysts forecast PRA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 24.240

Low

Averages

High

Current: 24.240

Low

Averages

High

Piper Sandler

Paul Newsome

Neutral

maintain

$18 -> $25

AI Analysis

2025-05-08

Reason

Piper Sandler

Paul Newsome

Price Target

$18 -> $25

AI Analysis

2025-05-08

maintain

Neutral

Reason

Piper Sandler analyst Paul Newsome raised the firm's price target on ProAssurance to $25 from $18 and keeps a Neutral rating on the shares. The firm notes the company reported a miss versus PSC and consensus. Underwriting results were worse than expected, but top-line results were higher than Piper expected and premiums in the company's medical malpractice business were stable. Bottom-line results were impacted by non-operating items totaling $12.6M related to its merger with The Doctors Company, the firm adds.

Citizens Capital Markets

Matthew Carletti

Buy

Hold

Downgrades

n/a

2025-04-03

Reason

Citizens Capital Markets

Matthew Carletti

Price Target

n/a

2025-04-03

Downgrades

Buy

Hold

Reason

Citizens JMP analyst Matthew Carletti downgraded ProAssurance to Market Perform from Outperform without a price target following the announcement that the company will be acquired by The Doctors Company. With the shares currently trading at a 6% discount to Doctors' $25.00 acquisition price, the market is currently fairly discounting the potential outcomes, the analyst tells investors in a research note. Citizens says that while a better, competing offer can never be ruled out, it believes the odds are "quite low."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRA

Unlock Now

PRA Should I Buy

PRA Should I Buy

Should You Buy ProAssurance Corp (PRA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch